2023年1月20日

組織>薩爾瓦多Scaffidi,於2020年加入Ysios獎學金計劃,已經晉升為副教授。> Ysios也將Sanifit聯合創始人兼首席執行官瓊Perello作為合資企業的合作夥伴。>這些任命添加操作能力支持Ysios’任務建立領先的生命科學公司。Ysios資本歐洲生命科學風險資本公司,今天宣布晉升喬迪Xiol夥伴和薩爾瓦多Scaffidi關聯,以及任命瓊Perello作為合資企業的合作夥伴。喬迪Xiol於2019年加入Ysios資本助理和他的貢獻投資機會的識別和評價優秀。加入Ysios之前,喬迪在維達公司在波士頓,在那裏他專注於腫瘤帶來的機遇、基因治療、眼科。在他的新角色,他將負責製定和管理投資。他目前的董事會成員Northsea療法和拚接生物,和一個觀察者Adcendo和Cytoki的董事會。薩爾瓦多Scaffidi加入Ysios資本分析師在2021年成功完成後Ysios’獎學金計劃。加入Ysios之前,薩爾瓦多收到巴塞羅那大學的博士學位(烏蘭巴托),在那裏他學習了使用生物物理技術protein-ligand複合物。 As an Associate, he will source and evaluate investment opportunities. Salvatore is currently a board observer at Splice Bio. “The human capital is our key and only asset. These promotions reflect our commitment to foster and value top talent.” commented Joël Jean-Mairet, Managing Partner at Ysios Capital. Joan Perelló, a highly accomplished serial life sciences entrepreneur, has been appointed as a new Venture Partner at Ysios Capital. With 15+ years of management experience in various organizations, including as CEO, Non-Executive Director, President and Chairman, Joan Perelló is a respected figure in the life sciences industry. He is co-founder and CEO of Sanifit, a biotech company that raised over €140M in equity and debt financing before it was acquired by Vifor for €375M + sales milestones, the biggest exit of the Spanish Biotech sector. Joan is Chairman of the Board at CIRCE Crystal Engineering, President of the Balearic Cluster of Biotechnology and Biomedicine and Vice-Dean at the Official College of Chemists in the Balearic Islands, Spain. Joan Perelló holds an MSc in Chemistry with first-class honors and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical and Clinical Chemistry as an Associate Professor. “I have known the Ysios team for over a decade and have long admired their work in building Europe’s, and in particular Spain’s, leading life sciences companies. With their strong brand, international network, and excellent scientific backgrounds, they transform capital into medical breakthroughs.” commented Joan Perelló, Venture Partner at Ysios Capital. Julia Salaverria, Managing Partner at Ysios also added: “Joan is a highly accomplished serial entrepreneur and has created one of the key success stories in Spain. We are honored to be working with him as we continue to build leading life sciences companies.” Joan Perelló will join Ysios Capital Venture Partners’ base of internationally renowned experts currently formed by Toni Ribas, world expert in immuno-oncology, former President of the American Association for Cancer Research (AACR) and Professor at the University of California Los Angeles (UCLA); Pamela Klein, former VP Development at Genentech/Roche; Carlos Payá, expert in Immunology and infectious diseases, previously in various leadership roles at Eli Lilly in and CEO of Immune Design until its acquisition by Merck & Co., David Lacey, former Senior VP and Global Head of Discovery Research at Amgen, and Lance Berman who has more than 20 years of clinical development experience in big pharma and the biotech start-ups. About Ysios Capital Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet needs. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs. Ysios Capital was founded in 2008 and has over 400M€ million in assets under management through its three funds. For more information, please visit www.ysioscapital.com Contact